相似文献
1
CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors.
Cell. 2020 Apr 2;181(1):136-150. doi: 10.1016/j.cell.2020.03.023.
2
Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina.
Methods Mol Biol. 2018;1715:113-133. doi: 10.1007/978-1-4939-7522-8_9.
3
Evolving AAV-delivered therapeutics towards ultimate cures.
J Mol Med (Berl). 2021 May;99(5):593-617. doi: 10.1007/s00109-020-02034-2. Epub 2021 Feb 16.
4
In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
Bioconjug Chem. 2017 Apr 19;28(4):880-884. doi: 10.1021/acs.bioconjchem.7b00057. Epub 2017 Mar 17.
5
CRISPR Systems Suitable for Single AAV Vector Delivery.
Curr Gene Ther. 2022;22(1):1-14. doi: 10.2174/1566523221666211006120355.
6
Viral Delivery of Compact CRISPR-Cas12f for Gene Editing Applications.
CRISPR J. 2024 Jun;7(3):150-155. doi: 10.1089/crispr.2024.0010. Epub 2024 May 2.
7
Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors.
Int J Mol Sci. 2020 Oct 5;21(19):7353. doi: 10.3390/ijms21197353.
8
Use of AAV Vectors for CRISPR-Mediated In Vivo Genome Editing in the Retina.
Methods Mol Biol. 2019;1950:123-139. doi: 10.1007/978-1-4939-9139-6_7.
9
Delivery of CRISPR/Cas9 system by AAV as vectors for gene therapy.
Gene. 2024 Nov 15;927:148733. doi: 10.1016/j.gene.2024.148733. Epub 2024 Jun 28.
10
Ocular delivery of CRISPR/Cas genome editing components for treatment of eye diseases.
Adv Drug Deliv Rev. 2021 Jan;168:181-195. doi: 10.1016/j.addr.2020.06.011. Epub 2020 Jun 27.
引用本文的文献
1
CRISPR/Cas9 in colorectal cancer: Revolutionizing precision oncology through genome editing and targeted therapeutics.
Iran J Basic Med Sci. 2025;28(10):1279-1300. doi: 10.22038/ijbms.2025.87531.18902.
2
Advancing gene editing therapeutics: Clinical trials and innovative delivery systems across diverse diseases.
Mol Ther Nucleic Acids. 2025 Aug 5;36(3):102666. doi: 10.1016/j.omtn.2025.102666. eCollection 2025 Sep 9.
3
CRISPR in Neurodegenerative Diseases Treatment: An Alternative Approach to Current Therapies.
Genes (Basel). 2025 Jul 22;16(8):850. doi: 10.3390/genes16080850.
4
From Microbial Switches to Metabolic Sensors: Rewiring the Gut-Brain Kynurenine Circuit.
Biomedicines. 2025 Aug 19;13(8):2020. doi: 10.3390/biomedicines13082020.
5
Programmable epigenome editing by transient delivery of CRISPR epigenome editor ribonucleoproteins.
Nat Commun. 2025 Aug 26;16(1):7948. doi: 10.1038/s41467-025-63167-x.
6
CRISPR/Cas9 a genomic engineering technology for treatment in ALS mouse models.
Regen Ther. 2025 Aug 13;30:575-583. doi: 10.1016/j.reth.2025.07.009. eCollection 2025 Dec.
7
Towards the elimination of infectious HPV: exploiting CRISPR/Cas innovations.
Front Cell Infect Microbiol. 2025 Aug 4;15:1627668. doi: 10.3389/fcimb.2025.1627668. eCollection 2025.
8
Viral and nonviral nanocarriers for CRISPR-based gene editing.
Nano Res. 2024 Oct;17(10):8904-8925. doi: 10.1007/s12274-024-6748-5. Epub 2024 Jun 20.
9
Genome Editing Breeding with CRISPR-Cas Nucleases, Base Editors, and Prime Editors.
Animals (Basel). 2025 Jul 22;15(15):2161. doi: 10.3390/ani15152161.
10
Trends and challenges of AAV-delivered gene editing therapeutics for CNS disorders: Implications for neurodegenerative disease.
Mol Ther Nucleic Acids. 2025 Jul 17;36(3):102635. doi: 10.1016/j.omtn.2025.102635. eCollection 2025 Sep 9.
本文引用的文献
1
A mutation-independent CRISPR-Cas9-mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency.
Sci Adv. 2020 Feb 12;6(7):eaax5701. doi: 10.1126/sciadv.aax5701. eCollection 2020 Feb.
2
The promise and challenge of therapeutic genome editing.
Nature. 2020 Feb;578(7794):229-236. doi: 10.1038/s41586-020-1978-5. Epub 2020 Feb 12.
3
Treatment of a Mouse Model of ALS by In Vivo Base Editing.
Mol Ther. 2020 Apr 8;28(4):1177-1189. doi: 10.1016/j.ymthe.2020.01.005. Epub 2020 Jan 14.
4
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.
Mol Ther. 2020 Mar 4;28(3):723-746. doi: 10.1016/j.ymthe.2019.12.010. Epub 2020 Jan 10.
5
Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses.
Nat Biomed Eng. 2020 Jan;4(1):97-110. doi: 10.1038/s41551-019-0501-5. Epub 2020 Jan 14.
6
Can Adeno-Associated Viral Vectors Deliver Effectively Large Genes?
Hum Gene Ther. 2020 Jan;31(1-2):47-56. doi: 10.1089/hum.2019.220. Epub 2020 Jan 9.
7
Ex Vivo/In vivo Gene Editing in Hepatocytes Using "All-in-One" CRISPR-Adeno-Associated Virus Vectors with a Self-Linearizing Repair Template.
iScience. 2020 Jan 24;23(1):100764. doi: 10.1016/j.isci.2019.100764. Epub 2019 Dec 12.
8
Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 May;12(3):e1609. doi: 10.1002/wnan.1609. Epub 2019 Dec 2.
9
Advances in genome editing through control of DNA repair pathways.
Nat Cell Biol. 2019 Dec;21(12):1468-1478. doi: 10.1038/s41556-019-0425-z. Epub 2019 Dec 2.
10
Rational designs of in vivo CRISPR-Cas delivery systems.
Adv Drug Deliv Rev. 2021 Jan;168:3-29. doi: 10.1016/j.addr.2019.11.005. Epub 2019 Nov 21.
Zotero 插件